Close

What are ADC's

Our services

ADC Review
is made possible by:




NCT01156753 / Emerge Trial (CLINICAL TRIAL / GLEMBATUMUMAB VEDOTIN / CDX-011 / CR011-VCMMAE)

Study Title 
A Study of CDX-011 (CR011-vcMMAE) in Patients With Advanced GPNMB-expressing Breast Cancer (EMERGE) (NCT01156753)

Trial Description
The main purpose of this study is to see whether glembatumumab vedotin (also known as CDX-011 or CR011-vcMMAE) is effective in treating patients who have advanced breast cancer that makes a protein called glycoprotein NMB (GPNMB), and who have already received (or were not candidates for) all available approved therapies for their breast cancer. This study will also further characterize the safety of CDX-011 treatment in this patient population.

This trial is sponsored by Celldex Therapeutics. [1]

Study Data

  • Condition: Breast Cancer
  • Interventions:
    • Drugs used in this trial
  • Phase: II
  • Enrollment: 120
  • Start: July 2010
  • Study Completion: November 2012
  • Last verified: December 2012

Study Schematic 

NCT01156753 / EMERGE TRIAL (CLINICAL TRIAL / GLEMBATUMUMAB VEDOTIN / CDX-011 / CR011-VCMMAE)


Last Editorial review: July 29, 2016
Information based on ClinicalTrials.gov (NIH/NCI) and other sources.

Copyright © 2015-2016 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.

Add to Flipboard Magazine.


Share

Recommended Articles

Four Ways to Show Nonobviousness of ADC Inventions

05 October, 2018

When the first antibody-drug conjugate (ADC) was approved by the U.S. Food and Drug Administration (FDA) in 2000,[1] only a handful of patent applications claiming ADCs had been published.[2] As research cont...


Skip to toolbar